Active, Closed, Last funding round type (e.g. The approval of GBTs medicine for SCD was expanded to treat children ages 4 years to less than 12 years. Nisa Investment Advisors LLC now owns 1,510 shares of the companys stock worth $52,000 after acquiring an additional 650 shares during the period. This site uses cookies to give you the best online experience. Twelve research analysts have rated the stock with a hold rating and four have issued a buy rating to the companys stock. Nisa Investment Advisors LLC now owns 2,110 shares of the company's stock. Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. published in The New England Journal of Medicine. Download as csv Download as Excel. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Global Blood Therape specific information freely available to individual and institutional investors to make a timely investment decision. Pfizer has completed its acquisition of all the outstanding shares of common stock of GBT for $68.50 per share in cash for an estimated total enterprise value of approximately $5.4 billion, including debt and net of cash acquired. GBT is working to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease Our goal is to transform the treatment of sickle cell disease (SCD), an overlooked rare condition, and help address the urgent needs of the community. GBTs medicine is the first treatment approved by the FDA to target an underlying cause of SCD. View, Preferred Dividends Income Statement Impact, Disposition of 5376 shares by Dawn Svoronos of Global Blood subject to Rule 16b-3, Exercise or conversion by Habibizad Nazila of 182 shares of Global Blood subject to Rule 16b-3, Exercise or conversion by Habibizad Nazila of tradable shares of Global Blood subject to Rule 16b-3, Exercise or conversion by Habibizad Nazila of 2208 shares of Global Blood subject to Rule 16b-3, Sale by Habibizad Nazila of 4678 shares of Global Blood, Sale by Dawn Svoronos of 1908 shares of Global Blood, Acquisition by Thompson Alexis A of 3600 shares of Global Blood subject to Rule 16b-3, Exercise or conversion by Smithwhitley Kim of 6040 shares of Global Blood subject to Rule 16b-3, Exercise or conversion by Habibizad Nazila of 183 shares of Global Blood subject to Rule 16b-3, Payment of 540 shares by Habibizad Nazila of Global Blood subject to Rule 16b-3, Exercise or conversion by Thompson Alexis A of 2400 shares of Global Blood subject to Rule 16b-3, Acquisition by Habibizad Nazila of 28628 shares of Global Blood subject to Rule 16b-3, predict the probability of Global Blood's future price movements, Sponsored content. The Company focuses on discovering, developing, and commercializing therapeutics. Our goal is to transform the treatment of sickle cell disease (SCD), an overlooked rare condition, and help address the urgent needs of the community. Pfizer Inc said on Monday it has agreed to buy blood disorder drugmaker Global Blood Therapeutics in a $5.4 billion deal. One of the main advantages they have over retail investors is the fees paid for trades. August 4, 2022 Press Release. Click the image for more detail . Global Blood Therapeutics 2 years 4 months Associate Director, Biologics CMC Analytical Development Global Blood Therapeutics Aug 2022 - Present 4 months. Global Blood Therapeutics, Inc. shareholders might be concerned after seeing the share price drop 16% in the last quarter. Posted by Defense World Staff on Oct 28th, 2022. Zim Integrated Shipping Services Stock: High Yield or High Risk? Global Blood Therapeutics acquired by Pfizer, Name of the organization that made the acquisition, Stock ticker symbol (e.g. GBT is now part of Pfizer! * Investors with a full data subscription can access data for any fund and any ticker. PolymErization) Study was designed to assess the efficacy of voxelotor SEC filings are important regulatory documents required of all public companies to provide to potential investors. Global Blood Therapeutics has a total of sixty-four million four hundred fifty thousand. Global Blood Therapeutics (GBT) is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. According to Global Blood, roughly half of all sickle cell patients have one or more. These cookies will be stored in your browser only with your consent. Learn More about Eric Fink's net worth. GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease. This molecule would later be named voxelotor. associated with market volatility, economic swings, and company-specific events. Nisa Investment Advisors LLC lifted its stake in shares of Global Blood Therapeutics by 39.7% in the 2nd quarter. Please. Hourglass Capital LLC Has $418,000 Holdings in JPMorgan Chase & Co. JPMorgan Chase & Co. The estimated net worth of Eric Fink is at least $349,348.09 as of May 10th, 2021. drugs that have demonstrated preliminary clinical evidence indicating GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Want to be notified whenever an investor makes a significant change to their holdings of Global Blood Therapeutics In? Following the completion of the transaction, the insider now directly owns 8,918 shares of the companys stock, valued at $599,200.42. Can Mid-Cap Lantheus Continue its 2022 Outperformance? GBT Announces New Employment Inducement Grants. GBTs first medicine for SCD received accelerated approval in the U.S. three months prior to our PDUFA date. GBT is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with SCD who are 12 years of age and older. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. It also is working on GBT021601, a potential next-generation sickle hemoglobin. Click here for more information. Priority Review is granted to therapies that the FDA determines have the potential to provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition. Download as csv Download as Excel. Analyze quarterly positions in Global Blood Therapeutics with up to 7 years of data, all consolidated into one spreadsheet . ProShare Advisors LLC lessened its holdings in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT Get Rating) by 34.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. This data is downloadable for data subscribers. It was founded in 2012 and is headquartered in San. Mizuho Markets Americas LLC now owns 255,749 shares of the company's stock worth $17,417,000 after purchasing an additional 67,468 shares during the period. Are you sure you want to proceed? Endurant Capital Management LP now owns 43,250 shares of the companys stock worth $1,498,000 after purchasing an additional 453 shares during the last quarter. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Global Blood, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. Candriam Luxembourg S.C.A. Topline results for all patients enrolled in the Phase 3 HOPE Study were GBT is now a wholly owned subsidiary of Pfizer. Exhibit Description Number 2.1 Agreement and Plan of Merger, dated as of August 7, 2022, by and among Pfizer Inc., Ribeye Acquisition Corp. and Global Blood Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to Global Blood Therapeutics, Inc.'s Current Report on Form 8-K filed on August 8, 2022) 3.1 Amended and Restated Certificate of . AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Global Blood Therapeutics. But that scarcely detracts from the really solid long term returns . The ACCEL Grants Program provides funding to support the development of sustainable access to care programs for people with SCD in the U.S. Breakthrough Therapy designation expedites the development and review of Victory Capital Management Inc. Trims Holdings in The Marcus Co. (NYSE:MCS), Victory Capital Management Inc. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Nisa Investment Advisors LLC raised its holdings in shares of Global Blood Therapeutics by 75.6% during the 1st quarter. Javascript is disabled or is not supported by your browser. New York State Common Retirement Fund raised its holdings in shares of Global Blood Therapeutics by 1.1% during the 1st quarter. SkyView Investment Advisors LLC now owns 804 shares of the companys stock worth $28,000 after acquiring an additional 687 shares during the period. Finally, SkyView Investment Advisors LLC raised its holdings in shares of Global Blood Therapeutics by 587.2% during the 1st quarter. Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology. The company was founded to develop medicines that could make a The company is currently focusing on the development of its initial. Founded in 2011, GBT is delivering on its goal to transform the . The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. That amount is more than double the company's nearly $225 million in long-term debt at the end of . Sales of its sickle cell . This deal was done in Cash. This is. At $250 million, Global Blood Therapeutics' isn't overwhelming, but it's not exactly small either. Pfizer will pay $68.50 per GBT share, which represents a 7.3% premium to its Friday closing price and a nearly 43% premium over Thursday's closing price after Bloomberg reported that GBT had . In this article GBT +0.01 (+0.01%) PFE +0.18 (+0.41%) Follow your. But increased research and . WhatsApp acquired by Facebook), Total number of sub-organizations that belongs to a parent Organization. Add alert for GBT Ticker: GBT; CUSIP Number: 37890u108; Tip: Access positions for across all investors. Global Blood Therapeutics, Inc. has a 52-week . The company has a debt-to-equity ratio of 4.92, a quick ratio of 6.17 and a current ratio of 6.88. As they are buying in large quantities, they can manage their cost more effectively. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. Voxelotor became the first potential treatment for SCD to be accepted We also use third-party cookies that help us analyze and understand how you use this website. Cantor Fitzgerald restated a neutral rating on shares of Global Blood Therapeutics in a report on Wednesday, September 21st. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $65.32. ProShare Advisors LLCs holdings in Global Blood Therapeutics were worth $386,000 at the end of the most recent quarter. SVB Leerink lowered Global Blood Therapeutics from an outperform rating to a market perform rating and set a $68.50 price target on the stock. The stock was sold at an average price of $67.19, for a total value of $314,314.82. The FDA also approved Oxbryta tablets for oral suspension, a new dispersible tablet dosage form. You are currently leaving our site. HR has also turned over completely. the potential for substantial improvement over available therapy. Find More Contacts for Global Blood Therapeutics, Edit Lists Featuring This Company Section. GBT is collaborating with Syros to discover new medicines that induce fetal hemoglobin to treat SCD and beta thalassemia. These cookies do not store any personal information. See insights on GBT (Global Blood Therapeutics) including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. As you can see below, at the end of March 2020, Global Blood Therapeutics had US$73.7m of debt, up from none a year ago. Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honored Oxbryta as the Best Biotechnology Product for 2021. Show The GBT Foundation Division The fund owned 12,069 shares of the companys stock after selling 6,255 shares during the quarter. Who owns Global Blood Therapeutics In? View contacts for Global Blood Therapeutics to access new leads and connect with decision-makers. GBT Announces Participation at the Wedbush PacGrow Healthcare Conference. frequent and early interactions with the EMA to accelerate evaluation Global Blood operates under Biotechnology classification in the United States and is traded on NMS Exchange. Although the fundamental cause of SCD has been understood for decades, therapeutic innovation and access to care has significantly lagged. Who bought or sold Global Blood Therapeutics In this quarter? Elkhorn Partners Limited Partnership now owns 16,950 shares of the company's stock worth $587,000 after buying an additional 2,150 shares during the period. They can put in a lot of research and financial analysis when reviewing investment options. You also have the option to opt-out of these cookies. Pfizer completes acquisition of Global Blood Therapeutics, Global Blood Therapeutics' tough negotiating led Pfizer to boost its buyout offer 3 times, filing shows, Where Global Blood Therapeutics Stands With Analysts, United States Acquired Companies With More Than 500 Employees, California Companies With More Than $1M in Revenue (Top 10K), California Companies With Less Than $500M in Revenue (Top 10K), California Companies With More Than 100 Employees (Top 10K). Copyright 2021 Which industries do these Sub-Organization operate in? StockNews.com initiated coverage on shares of Global Blood Therapeutics in a report on Friday. Equities research analysts at StockNews.com initiated coverage on shares of Global Blood Therapeutics (NASDAQ:GBT - Get Rating) in a research note issued to investors on Friday. Invests $11.80 Million in EVO Payments, Inc. (NASDAQ:EVOP), Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT), The One Question that Matters for Altria Stock. Several research firms have recently commented on GBT. The business has a 50-day simple moving average of $68.03 and a 200-day simple moving average of $45.79. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Transaction Name Global Blood Therapeutics acquired by Pfizer Acquired by Pfizer Announced Date Aug 8, 2022 Price $5.4B Sub-Organizations Number of Sub-Orgs 1 Which industries do these Sub-Organization operate in? NASDAQ:GBT opened at $68.49 on Friday. You are now leaving the Global Blood Therapeutics website. You are currently leaving our site. Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics, as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment. The firm has a market capitalization of $4.62 billion, a price-to-earnings ratio of -13.67 and a beta of 0.45. in a report on Tuesday, August 9th. For the quarter, Global Blood Therapeutics' sales hit nearly $55.2 million, representing quite an encouraging improvement over the year-ago quarter's $39 million. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. SkyView Investment Advisors LLC now owns 804 shares of. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Morrison sold 4,800 shares of Global Blood Therapeutics at a price of $30.21 per share.. Candriam Luxembourg S.C.A. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. and potential marketing approval. This website uses cookies to improve your experience while you navigate through the website. In related news, insider Nazila Habibizad sold 4,678 shares of the companys stock in a transaction that occurred on Thursday, August 18th. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Phosphate plays an important role in cell function and . Shares of Global Blood Therapeutics ( GBT) closed at $35.02 on Wednesday, up 7.9% from the day before and rebounding two days after the stock hit a 52-week low at $31.90. This net worth approximation does not reflect any other investments that Mr. Fink may own. Arizona State Retirement System raised its holdings in shares of Global Blood Therapeutics by 3.7% during the 1st quarter. Global Blood Therapeutics 17,044 followers 1mo Today, Congresswoman Barbara Lee of California, Congressman Danny Davis of Illinois, Senator Chris Van Hollen of Maryland and Senator Cory Booker of. Global Blood Therapeutics Inc Global Blood Therapeutics, Inc. operates as a biopharmaceutical company. Past performance is a poor indicator of future performance. Global Blood Therapeutics Inc operates in the healthcare sector of the United States. Management will also keep very unprofessional and disruptive staff in place, regardless of the number of complaints received by the team, creating even further deterioration of morale. Oppenheimer lowered Global Blood Therapeutics to a market perform rating in a report on Monday, August 15th. Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). August 3, 2022 Press Release. Connor, Clark & Lunn Investment Management, State of New Jersey Common Pension Fund D, OTR - Nominee Name for The State Teachers Retirement Board of Ohio, Track 13F-HR Filings for Hedge Funds and Value Investors. External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Global Blood Therapeutics. The company's lead product candidate is voxelotor (previously known as GBT440), an oral, once-daily therapy that modulates hemoglobin's affinity . Shares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Senior Manager, Biologics CMC Analytical . The Institutions Box Up Dividend Growth with These Cheap Stocks, Be Sure You Own United Parcel Service for the Right Reasons, MarketBeat.com's FREE daily email newsletter. Global Blood Therapeutics is testing it to see if it can reduce the frequency of vaso-occlusive crises. Global hyperphosphatemia therapeutics market was valued at USD 2.46 billion in 2021, and it is expected to reach USD 3.53 billion by 2028 at a CAGR of 5.3 % over the forecast period (2022-2028).Westford, USA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hyperphosphatemia is a condition characterized by elevated levels of phosphate in the blood. Some institutional investors establish a significant position in stocks such as Global Blood in order to find ways to drive up its value. Voxelotor is staring at a multi-billion dollar opportunity In December 2018, Global Blood Therapeutics announced FDA's acceptance of the proposal relating to the use of accelerated approval. for the EUs new Priority Medicines (PRIME) designation, enabling Analyze quarterly positions in Global Blood Therapeutics In with up to 7 years of data, all consolidated into one spreadsheet . The GBT Foundation is a community-focused, charitable entity that seeks to improve the health and well-being of underserved patient communities around the world, particularly for people living with SCD. transformative impact, and SCD was our first focus. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Top investors of Global Blood . Within 15 months of voxelotor being identified as a potential clinical boosted its stake in shares of Global Blood Therapeutics by 16.7% in the first quarter. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Considering cash on hand (>$500M), the company's enterprise value is near $3.5B. Following the transaction, Morrison still owns 3,037 shares of the company, worth $84,914. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Mr. Fink owns 5,161 shares of Global Blood Therapeutics stock worth more than $349,348 as of September 21st. Learn more, including how to disable certain cookies on our, GBT Wins Prestigious Prix Galien USA Award for Oxbryta, Complete Analysis of Phase 3 HOPE Study of Oxbryta Published in, European Medicines Agency (EMA) Accepts Marketing Authorization Application (MAA) for Oxbryta, GBT Partners with Syros Pharmaceuticals to Develop Novel Therapies for SCD and Beta Thalassemia, Voxelotor NDA Seeking Accelerated Approval Accepted by the U.S. FDA Under Priority Review, GBT Launches Access to Excellent Care for Sickle Cell Patients (ACCEL) Grants Program. Are you sure you want to proceed? Analyze quarterly positions in Global Blood Therapeutics In with up to 7 years of data, all consolidated into one spreadsheet. GBT began testing GBT440 in 2012 to understand its mechanism of action. Position Increased by Iowa State Bank, JPMorgan Chase & Co. Shares Sold by OLD Second National Bank of Aurora, Illinois Municipal Retirement Fund Increases Stake in Ecolab Inc. (NYSE:ECL), Skyworks Solutions, Inc. (NASDAQ:SWKS) Shares Sold by abrdn plc, QUALCOMM (NASDAQ:QCOM) Price Target Cut to $165.00 by Analysts at Canaccord Genuity Group, Hourglass Capital LLC Has $418,000 Holdings in JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM) Position Increased by Iowa State Bank, JPMorgan Chase & Co. (NYSE:JPM) Shares Sold by OLD Second National Bank of Aurora, Deseret Mutual Benefit Administrators Buys 1,851 Shares of JPMorgan Chase & Co. (NYSE:JPM), abrdn plc Grows Stock Holdings in Block, Inc. (NYSE:SQ), Illinois Municipal Retirement Fund Cuts Stock Position in TE Connectivity Ltd. (NYSE:TEL), Johnson & Johnson (NYSE:JNJ) Shares Purchased by Aviva PLC, Steward Partners Investment Advisory LLC Purchases 1,104 Shares of Pembina Pipeline Co. (NYSE:PBA), abrdn plc Cuts Stock Position in Dover Co. (NYSE:DOV), Douglas Elliman Inc. (NYSE:DOUG) Shares Bought by Los Angeles Capital Management LLC, abrdn plc Has $4.02 Million Stock Holdings in FLEETCOR Technologies, Inc. (NYSE:FLT), Los Angeles Capital Management LLC Has $1.48 Million Stock Position in Rocket Companies, Inc. (NYSE:RKT), Scotia Capital Inc. Cuts Stake in Edwards Lifesciences Co. (NYSE:EW), Scotia Capital Inc. Boosts Stock Holdings in VeriSign, Inc. (NASDAQ:VRSN), Bank of Nova Scotia Sells 36,660 Shares of Lumen Technologies, Inc. (NYSE:LUMN), Bank of Nova Scotia Invests $892,000 in Prosperity Bancshares, Inc. (NYSE:PB), Bank of Nova Scotia Has $857,000 Stock Position in H&R Block, Inc. (NYSE:HRB).